A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults

European Journal of Haematology

Volumn 85, Issue 2, 2010, Pages 177-179

  Giraldez, Miriam ^a   Puto, Katarzyna ^b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b University of Miami Jackson Memorial Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; LACTATE DEHYDROGENASE; RASBURICASE; URIC ACID;

ADULT; CLINICAL ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ECONOMIC EVALUATION; FEMALE; HEMODIALYSIS; HUMAN; HUMAN CELL; KIDNEY DISEASE; LACTATE DEHYDROGENASE BLOOD LEVEL; LETTER; LEUKOCYTE; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SINGLE DRUG DOSE; STUDENT T TEST; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; URIC ACID BLOOD LEVEL;

ADOLESCENT; ADULT; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR LYSIS SYNDROME; URATE OXIDASE; URIC ACID; YOUNG ADULT;

EID: 77954731566     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01457.x     Document Type: Letter

References (15)

1. Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ. Pathophysiology, Clinical Consequences, and Treatment of Tumor Lysis Syndrome. Am J Med 2004 116 : 546 554.
2. Goldman SC, Holcenberg JS, Finklestein JZ, Hutchinson R, Kreissman S, Johnson FL, Tou C, Harvey E, Morris E, Cairo MS. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood 2001 97 : 2998 3003.
3. TM), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. Leukemia 2005 19 : 34 8.
4. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: an evidence-Based Review. J Clin Oncol 2008 26 (16 2767 2778.
5. FDA. Elitek Package Insert. Sanofi-Aventis. 2009. http://products.sanofi- aventis.us/elitek/elitek.html (30 October 2009).
6. EMEA. Fasturtec Package Insert. Sanofi-Aventis. 2009 http://www.emea. europa.eu/humandocs/Humans/EPAR/fasturtec.htm (5 September 2009).
7. Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-Dose Rasburicase in the Treatment of Adults with Hyperuricemia Associates with Malignancy. Pharmacotherapy 2006 26 (2 242 247.
8. Lee AC, Li CH, So KT, Chan R. Treatment of Impeding Tumor Lysis with single-Dose Rasburicase. Ann Pharmacother 2003 37 : 1614 1617.
9. Liu CY, Sims-McCallum RP, Schiffer CA. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy. Leuk Res 2005 29 : 463 465.
10. Trifilio S, Gordon L, Shingal S, Tallman M, Evens A, Rashid K, Fishman M, Masino K, Pi J, Mehta J. Reduced-dose rasburicase (recombinant xantine oxidase) in adult cancer patients with hyperuricemia. Bone Marrow Transplant 2006 37 : 997 1001.
11. Hummel M, Reiter S, Adam K, Hehlmann R, Buchheidt D. Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. Eur J Haematol 2008 80 (4 331 336.
12. Campara M, Shord SS, Haaf CM. Single-dose rasburicase for tumor lysis syndrome in adults: weight-based approach. J Clin Pharm Ther 2009 34 (2 207 213.
13. Reeves DJ, Bestul DJ. Evaluation of a single fixed dose of Rasburicase 7.5 mg for the Treatment of Hyperuricemia in Adults with Cancer. Pharmacotherapy 2008 28 (6 685 690.
14. Malaguarnera M, Vacante M, Russo C, Dipasquale G, Gargante MP, Motta M. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. Expert Opin Pharmacother 2009 10 (5 737 742.
15. McDonell AM, Lenz KL, Frei-Lahr DA, Hayslip J, Hall PD. Single-dose rasburicase 6 mg in the management of tumor lysis syndrome in adults. Pharmacotherapy 2006 26 (6 806 812.